Atara Biotherapeutics Inc
ATRAHealthcare|Biotechnology|USA
$9.72
-0.26 (-2.59%)
Financials
Financial Snapshot
Market Cap
$87.6M
Enterprise Value
$-1.7M
Revenue (TTM)
$23.1M
Net Income (TTM)
$-9.5M
Cash & Equivalents
—
Net Cash/Share
$-5.75
Free Cash Flow (TTM)
$-25.9M
Operating CF (TTM)
$-25.9M
Debt/Equity
-0.27
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$6.5M
Monthly Burn
$2.2M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $255.7M | $166.1M | $309.6M | $259.1M | $500.7M | $371.1M | $242.8M | $51.7M | $42.5M | $8.5M | $8.4M | |
| Operating Cash Flow | $-60.0M | $-87.5M | $-179.8M | $-235.6M | $-180.8M | $-220.5M | $-270.4M | $-193.0M | $-68.7M | $-50.9M | $-25.9M | |
| Free Cash Flow | $-63.0M | $-107.7M | $-215.7M | $-241.4M | $-185.3M | $-231.1M | $-274.6M | $-194.2M | $-69.0M | $-50.9M | $-25.9M | |
| Capital Expenditure | $-3.0M | $-20.2M | $-35.9M | $-5.7M | $-4.5M | $-10.6M | $-4.2M | $-1.2M | $-246.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $506.0K | $20.0M | $357.5M | $188.8M | $427.6M | $103.9M | $53.1M | $2.0M | $59.3M | $16.1M | $19.3M |
R&D Spending
R&D (TTM)
$10.2M
R&D Intensity
44.0%
R&D Growth YoY
-72.8%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.3M | $63.6M | $8.6M | $128.9M | $120.8M | $23.1M | |
| R&D Expense | $56.5M | $81.2M | $167.5M | $216.1M | $244.7M | $282.0M | $272.5M | $224.8M | $151.5M | $37.4M | $10.2M | |
| R&D % of Revenue | — | — | — | — | — | 1386.4% | 428.7% | 2622.0% | 117.5% | 31.0% | 44.0% | |
| SG&A | $24.7M | $40.3M | $69.7M | $79.6M | $64.4M | $78.8M | $71.6M | $50.9M | $39.9M | $26.3M | $17.8M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.3M | $63.6M | $8.6M | $128.9M | $120.8M | $23.1M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $8.9M | $21.0M | $21.2M | $897.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.3M | $63.6M | $-313.0K | $107.9M | $99.6M | $22.2M | |
| R&D | $56.5M | $81.2M | $167.5M | $216.1M | $244.7M | $282.0M | $272.5M | $224.8M | $151.5M | $37.4M | $10.2M | |
| SG&A | $24.7M | $40.3M | $69.7M | $79.6M | $64.4M | $78.8M | $71.6M | $50.9M | $39.9M | $26.3M | $17.8M | |
| Operating Income | $-81.2M | $-121.5M | $-237.1M | $-295.7M | $-309.1M | $-340.5M | $-280.5M | $-276.0M | $-83.4M | $35.9M | $-5.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-373.0K | $-5.3M | $-4.6M | $-3.8M | $-3.6M | |
| Pretax Income | $-79.0M | $-119.5M | $-230.7M | $-291.0M | $-306.6M | $-340.1M | $-228.3M | $-276.1M | $-85.4M | $32.7M | $-9.4M | |
| Net Income | $-79.0M | $-119.5M | $-230.7M | $-291.0M | $-306.6M | $-340.1M | $-228.3M | $-276.1M | $-85.4M | $32.7M | $-9.5M | |
| EPS (Diluted) | -68.75 | -100.00 | -131.75 | -141.75 | -103.75 | -90.75 | -56.00 | -65.19 | -11.41 | 2.57 | -0.78 | |
| EBITDA | $-80.9M | $-120.6M | $-233.4M | $-288.6M | $-300.7M | $-331.1M | $-222.3M | $-266.0M | $-75.7M | $38.6M | $-5.5M | |
| Shares Out. (M) | 1.15 | 1.20 | 1.75 | 2.05 | 2.96 | 3.75 | 4.08 | 4.24 | 7.49 | 12.72 | 14.08 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.0M | $79.2M | $60.7M | $74.3M | $200.4M | $106.1M | $92.9M | $25.8M | $25.0M | $8.5M | $8.4M | |
| Marketable Securities | $207.7M | $86.9M | $248.9M | $184.8M | $300.3M | $265.0M | $149.9M | $25.9M | $17.5M | $0.00 | $0.00 | |
| Total Current Assets | $260.6M | $172.2M | $321.5M | $273.0M | $523.3M | $384.6M | $295.1M | $101.9M | $64.9M | $12.2M | $12.2M | |
| Total Assets | $263.9M | $217.8M | $391.8M | $342.9M | $588.1M | $468.1M | $376.4M | $165.5M | $109.1M | $20.2M | $20.0M | |
| Total Current Liabilities | $9.7M | $27.6M | $40.0M | $36.7M | $82.9M | $105.8M | $78.9M | $142.2M | $134.6M | $14.9M | $5.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $10.2M | $39.9M | $53.0M | $52.2M | $125.8M | $188.5M | $249.8M | $264.7M | $206.4M | $58.7M | $57.3M | |
| Stockholders' Equity | $253.7M | $177.9M | $338.9M | $290.8M | $462.3M | $279.6M | $126.6M | $-99.2M | $-97.3M | $-38.5M | $-37.3M | |
| Retained Earnings | $-177.2M | $-296.6M | $-527.3M | $-818.0M | $-1.12B | $-1.46B | $-1.69B | $-1.97B | $-2.05B | $-2.02B | $-2.03B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-60.0M | $-87.5M | $-179.8M | $-235.6M | $-180.8M | $-220.5M | $-270.4M | $-193.0M | $-68.7M | $-50.9M | $-25.9M | |
| Capital Expenditure | $-3.0M | $-20.2M | $-35.9M | $-5.7M | $-4.5M | $-10.6M | $-4.2M | $-1.2M | $-246.0K | $0.00 | $0.00 | |
| Free Cash Flow | $-63.0M | $-107.7M | $-215.7M | $-241.4M | $-185.3M | $-231.1M | $-274.6M | $-194.2M | $-69.0M | $-50.9M | $-25.9M | |
| Investing Cash Flow | $83.7M | $99.9M | $-196.3M | $60.5M | $-120.7M | $22.3M | $203.0M | $123.9M | $8.6M | $18.1M | $949.0K | |
| Financing Cash Flow | $506.0K | $20.0M | $357.5M | $188.8M | $427.6M | $103.9M | $53.1M | $2.0M | $59.3M | $16.1M | $19.3M | |
| Issuance of Stock | $0.00 | $19.2M | $340.9M | $188.6M | $423.0M | $98.7M | $21.9M | $2.1M | $60.0M | $16.3M | $19.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $-528.0K | $-486.0K | $-389.0K | $-254.0K | $-518.0K | $-947.0K | $-892.0K | $-250.0K | $0.00 | |
| Stock Based Comp. | $16.8M | $23.1M | $33.8M | $51.7M | $51.4M | $53.9M | $53.8M | $45.4M | $27.0M | $9.8M | $6.3M | |
| Net Change in Cash | $24.2M | $32.5M | $-18.5M | $13.6M | $126.1M | $-94.3M | $-14.4M | $-67.1M | $-811.0K | $-16.7M | $-5.6M |
Dilution Tracker
Shares outstanding grew 275.8% over 5 years — significant dilution
Shares Outstanding
14M
5-Year Share Growth
+275.8%
Stock Issuance (TTM)
$19.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.15 | 1.20 | 1.75 | 2.05 | 2.96 | 3.75 | 4.08 | 4.24 | 7.49 | 12.72 | 14.08 | |
| YoY Change % | — | 4.0% | 46.6% | 17.1% | 44.2% | 26.6% | 8.9% | 3.8% | 76.8% | 69.8% | 10.7% | |
| Stock Issuance | $0.00 | $19.2M | $340.9M | $188.6M | $423.0M | $98.7M | $21.9M | $2.1M | $60.0M | $16.3M | $19.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $16.8M | $23.1M | $33.8M | $51.7M | $51.4M | $53.9M | $53.8M | $45.4M | $27.0M | $9.8M | $6.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -3.7% | 83.7% | 82.4% | 96.1% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1673.9% | -441.2% | -3219.5% | -64.7% | 29.7% | -24.8% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1672.3% | -359.1% | -3220.9% | -66.2% | 27.1% | -40.9% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1627.9% | -349.6% | -3102.7% | -58.7% | 32.0% | -23.7% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1136.2% | -432.0% | -2265.3% | -53.5% | -42.2% | -111.8% | |
| ROE % | -27.8% | -55.4% | -89.3% | -92.4% | -81.4% | -91.7% | -112.4% | -2014.9% | 0.0% | Negative Equity | 0.0% | |
| ROA % | -26.8% | -49.6% | -75.7% | -79.2% | -65.9% | -64.4% | -54.1% | -101.9% | -62.2% | 50.5% | -27.9% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 5.66 / 8.25
Industry Med.27.51
P/S5.30
Historical0.25 / 5.39 / 420.96
Industry Med.9.49
P/B—
Historical1.11 / 3.16 / 31.20
Industry Med.2.93
EV/EBITDA-16.29
Historical-30.25 / -0.64 / 11.49
Industry Med.13.02
EV/Revenue3.86
Historical-3.56 / 3.08 / 301.98
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | 7.04 | At Loss | |
| PS Ratio | - | - | - | - | - | 72.59 | 5.26 | 6.33 | 0.77 | 1.91 | 5.30 | |
| PB Ratio | 1.62 | 3.13 | 4.71 | 3.22 | 3.54 | 5.17 | 2.48 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA | -1.92 | -3.23 | -5.52 | -2.40 | -3.83 | -3.33 | -0.65 | -0.23 | -1.05 | 3.48 | -16.29 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.18 | 2.26 | 7.08 | 0.62 | 1.11 | 3.86 |
Analyst Estimates & Quality
Altman Z-Score
-140.34
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
-0.43
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $2.08M | $40.10M | $21.92M |
| Net Income | $-16.28M | $12.32M | $-4.20M |
| EPS | -1.19 | 0.90 | -0.30 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Business of developing therapeutics | $120.8M |
By Geography
| Segment | 2025 |
|---|---|
| U.S. | $120.8M |